

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE S  
01 AUG 14 PH 4

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Abbott Laboratories			
2. Address <input type="checkbox"/> Check if different than previously reported 1710 Rhode Island Avenue, N.W. Suite 300			
3. Principal Place of Business (if different from line 2) City: Abbott Park State/Zip (or Country) Illinois 60064			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
Cynthia B. Sensibaugh	202/659-8524	cynthia.sensibaugh@abbott.com	66-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #
			30001000

**TYPE OF REPORT** 8. Year 2001 Midyear (January 1-June 30)  OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_ 11. No Lobbying A

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center"><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>1,520,000.00</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate reporting method. See instructions for description of method.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>
---	--

Signature \_\_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

David W. Landside

**ISSUE UPDATE**

24. General lobbying issues previously reported that no longer pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	C p c

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant affiliated organization

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Form LD-2 (Rev. 6/98)

Page \_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

1. H.R. 2330 - Agriculture Appropriations FY 2002, funding for Women, Infants & Children program
2. Labor, HHS Appropriations FY 2002, funding for state AIDS Drug Assistance program under the Ryan White Act

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
David W. Landside	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

1. H.R. 2330 - Agriculture Appropriations FY 2002, amendment concerning reimport of prescription drugs
2. H.R. 526, S. 1052 - Patients' Bill of Rights
3. FDA review, enforcement and inspection activities

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
David W. Landside	
Cynthia B. Sensibaugh	
Rosemary T. Haas	
Francis X. Tirrell	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_





Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, p information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific lobbying issues

1. S.J. Res. 6 - Joint Resolution providing for Congressional disapproval of ru relating to ergonomics
2. H.R. 1241, S. 598 - to provide for the reissuance of a rule relating to ergo:

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
David W. Landsidle	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

1. H.R. 1624/S.913 - Access to Cancer Therapies Act of 2001
2. S.357 - Medicare Preservation and Improvement Act of 2001
3. S.358 - Medicare Prescription Drug and Modernization Act of 2001
4. H.R. 1089/S.554 - Access to Innovation for Medicare Patients Act of 2001
5. H.R. 1798/S.1066 - Medicare Patient Access to Preventive and Diagnostic Tests Act of 2001
6. Medicare/Medicaid coverage of anti-obesity drugs

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
David W. Landside	
Cynthia B. Sensibaugh	
Rosemary T. Haas	
Francis X. Tirrell	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



15. General issue area code MMM (cont'd)

16. Specific lobbying issues:

7. Medicare local medical review policies in South Carolina, Florida and Pennsy to reduce reimbursement for vitamin D therapy
8. Medicare program memorandum to reduce reimbursement for blood glucose testin
9. Ensure adequate Medicare reimbursement for new technologies to increase the safety of the blood supply



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide the information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

1. H.R. 41/S. 41 - permanent extension of the R&D tax credit
2. H.R. 2550 - Economic Revitalization Tax Act of 2001

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
David W. Landsidle	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_





Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

**16. Specific lobbying issues**

1. H.R. 1786/S.847 - To impose tariffs on certain casein and milk protein conc
2. Request for removal of lead acid batteries from the USTR's tariff retaliati in the European Union bananas case
3. Request to reduce Canadian tariffs on infant formula

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

**18. Name of each individual who acted as a lobbyist in this issue area**

Name	Covered Official Position (if applicable)
Mark E. Barmak	
David W. Landside	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature Cynthia B. Sensibaugh Date August 14, 20

Printed Name and Title Cynthia B. Sensibaugh - Director, Federal Government Affairs

